3 ms·

Last year, a Hb polymerization inhibitor came to market: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-voxelotor-sickle-cell-disea

Last year, a Hb polymerization inhibitor came to market: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-voxelotor-sickle-cell-disease https://www.fda.gov/drugs/resources-information-approved-dru... It's a remarkable breakthrough.

DoreenMichele 6y ago
Thank you. I searched for an explanation of what it does in layman's terms and found this: None of the currently approved drugs can modify the underlying pathology of the disease. Voxelotor, first of its kind, is an orally administered drug that can alter the underlying disease pathology (by increasing the affinity between Hb and oxygen) and inhibit sickling of red blood cells. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100618/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100618/